RHINOCORT ALLERGY Drug Patent Profile

When do Rhinocort Allergy patents expire, and when can generic versions of Rhinocort Allergy launch?

Rhinocort Allergy is a drug marketed by Kenvue Brands and is included in one NDA.

The generic ingredient in RHINOCORT ALLERGY is budesonide. There are twenty-two drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the budesonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rhinocort Allergy

A generic version of RHINOCORT ALLERGY was approved as budesonide by TEVA PHARMS on November 18^th, 2008.

Summary for RHINOCORT ALLERGY

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	64
Clinical Trials:	13
What excipients (inactive ingredients) are in RHINOCORT ALLERGY?	RHINOCORT ALLERGY excipients list
DailyMed Link:	RHINOCORT ALLERGY at DailyMed

Recent Clinical Trials for RHINOCORT ALLERGY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Washington	Phase 4
Patient-Centered Outcomes Research Institute	Phase 4
Virginia Commonwealth University	Phase 4

See all RHINOCORT ALLERGY clinical trials

Paragraph IV (Patent) Challenges for RHINOCORT ALLERGY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RHINOCORT ALLERGY	Nasal Spray	budesonide	0.032 mg (32 mcg)/spray	020746	1	2007-05-14

US Patents and Regulatory Information for RHINOCORT ALLERGY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kenvue Brands	RHINOCORT ALLERGY	budesonide	SPRAY, METERED;NASAL	020746-003	Mar 23, 2015		OTC	Yes	Yes

EU/EMA Drug Approvals for RHINOCORT ALLERGY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Dr. Falk Pharma GmbH	Jorveza	budesonide	EMEA/H/C/004655Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age).	Authorised	no	no	yes	2018-01-08
Stada Arzneimittel AG	Kinpeygo	budesonide	EMEA/H/C/005653Kinpeygo is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.	Authorised	no	no	yes	2022-07-15

International Patents for RHINOCORT ALLERGY

See the table below for patents covering RHINOCORT ALLERGY around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	239482
Austria	369118
Australia	5421198
Australia	726515

Supplementary Protection Certificates for RHINOCORT ALLERGY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0613371	SPC/GB02/033	United Kingdom		PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
2435024	LUC00208	Luxembourg		PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), DE GLYCOPYRRONIUM (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE BUDESONIDE (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1468 20201210
2435024	301102	Netherlands		PRODUCT NAME: COMBINATIE VAN FORMOTEROL (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN), GLYCOPYRROLAAT (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN) EN BUDESONIDE (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN); REGISTRATION NO/DATE: EU/1/20/1498 20201210
2435024	2021C/518	Belgium		PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210

Last updated: July 1, 2026

Rhinocort Allergy (budesonide) Market Dynamics and Financial Trajectory: Sales, Drivers, Competition, and Patent/Generic Timing

Rhinocort Allergy (budesonide intranasal) is an established, low-to-mid single digit share leader in the US intranasal corticosteroid (INCS) category, but growth has largely stabilized after earlier brand momentum. Financial trajectory is shaped by (1) generic erosion risk for budesonide nasal steroid products, (2) competitive pressure from other INCS brands and newer delivery systems, and (3) seasonal demand patterns that amplify quarter-to-quarter volatility. Below is a market and commercial map focused on US dynamics, payer access, channel mix, and the major IP and regulatory forces affecting forward revenue.

What is the current market size and growth rate for intranasal corticosteroids like Rhinocort Allergy?

INCS market demand is driven by allergic rhinitis prevalence, seasonal peaks, and managed-care formulary access. Budesonide (Rhinocort) competes across a broad shelf of therapeutics: branded INCS and authorized generics, with adoption often determined by coverage tier, step edits, and copay positioning.

Key demand characteristics

• Seasonality: Allergic rhinitis sales track spring and early summer peaks, with winter spikes in perennial allergic rhinitis pockets.
• Patient segmentation: Brand retention is strongest in patients with prior INCS success and in systems where budesonide is preferred due to copay and pharmacy benefit design.
• Formulation choice: Delivery technology differences and patient preference (spray feel, mist pattern) can shift mix even when active ingredient is the same.

US payer and channel mechanics that affect Rhinocort

• PBM tier placement: INCS products frequently compete on copay spreads and “preferred generic” dynamics.
• OTC vs Rx access: Rhinocort Allergy is positioned for allergic rhinitis treatment in a way that can intersect both Rx and consumer purchasing flows, which changes elasticity versus pure Rx products.

How has Rhinocort Allergy performed financially over the last 5 to 10 years?

The long-run trajectory is typically a brand curve with post-launch plateau and then flattening under generic and competitive brand pressure. For legacy budesonide intranasal franchises, financial performance generally follows this pattern:

• Early years: share gains and expansion as a patient option.
• Mid-stage: stabilization as formularies normalize INCS coverage.
• Later-stage: erosion pressure when cost-effective generics and competing INCS narrow value differentiation.

Practical indicators used by investors and commercial teams

• Category share vs absolute growth: Even when category demand grows modestly, the drug can stagnate if share leaks to preferred generics or higher-preference devices.
• Gross-to-net pressure: INCS pricing is sensitive to rebates and promotional intensity, especially where payer demand shifts to best-value products.

What matters for “financial trajectory” modeling

• Seasonal revenue volatility reduces confidence in annualized metrics without smoothing.
• Channel mix (pharmacy vs mass vs mail order) changes margin profile even when sell-through is stable.
• Payer contracting cycles can swing realized net sales more than wholesale trends.

What are the main market dynamics affecting Rhinocort Allergy demand?

Three forces dominate: competitive substitution within INCS, payer economics (rebates and copays), and patient adherence to intranasal regimens.

1) Competitive substitution inside INCS

Rhinocort Allergy competes against both:

• Branded INCS that differentiate via device or patient experience.
• Generics that remove brand-driven pricing power.

Substitution is most aggressive where:

• formularies prefer generics or specific INCS,
• step therapy is present,
• copays compress.

2) Payer economics and formulary switching

Formulary placement typically decides whether Rhinocort captures incremental demand. When budesonide intranasal is not “preferred,” net sales performance can flatten even as category demand rises.

3) Adherence and persistence in intranasal therapy

Intranasal therapy persistence is a core revenue driver:

• Patients using daily INCS dosing maintain symptom control and reduce rescue medication usage.
• Switch decisions often come from perceived efficacy, convenience, or device usability.

Which drugs compete most directly with Rhinocort Allergy?

The direct competitive set is other INCS for allergic rhinitis across prescription and pharmacy channels. Substitution typically occurs at the class level.

Competitive comparators that influence share

• Other intranasal budesonide formulations and authorized generics.
• Other INCS brands and devices with strong formulary penetration.
• Oral antihistamines and combination therapies can divert patients when nasal symptoms are not fully controlled, affecting INCS refill rates.

How does patent and generic timing influence Rhinocort Allergy revenues?

Budesonide intranasal products in the US have faced generic competition over time across formulation and product-life cycles. For a mature INCS like Rhinocort Allergy, the key question for future financial trajectory is not “whether generics exist,” but whether any remaining product-specific exclusivities or formulation patents delay substitution for particular strengths, devices, or dosing regimens.

What to track for revenue impact

• Orange Book listings for budesonide nasal products that map to specific NDA/ANDA references.
• Any pediatric exclusivity or exclusivity extensions tied to labeling or formulation.
• The earliest ANDA commercial marketing dates that could pressure net pricing.

What is the Orange Book status of Rhinocort Allergy and budesonide nasal products?

A reliable Orange Book read depends on the specific NDA number and referenced product configuration (strength, dosage form, package). Without those exact identifiers, a complete Orange Book status mapping cannot be produced to a litigation-usable standard.

What patent estate strength exists for Rhinocort Allergy (budesonide intranasal)?

For mature budesonide INCS franchises, remaining “estate value” is often concentrated in:

• formulation-specific IP (device, suspension parameters, particle engineering),
• method-of-use claims tied to dosing or patient subsets,
• process/manufacturing claims.

A full estate strength assessment requires product-specific Orange Book and patent family mapping tied to the listed NDA.

Are there Paragraph IV challenges or ANDA litigation risks for Rhinocort Allergy?

Paragraph IV risk is typically highest when:

• a brand has late-expiring patents tied to a specific NDA,
• the sponsor’s exclusivities cover a formulation or dosing regimen still protected.

For a mature budesonide intranasal product, ANDA challenges may have already occurred historically, and current risk depends on any still-protected remaining claims.

How does FDA regulatory status shape Rhinocort Allergy commercialization?

For intranasal corticosteroids, regulatory status affects launch readiness, labeling-based promotion limits, and substitution dynamics via automatic generic approvals. Two commercial implications matter most:

• Labeling and dosing instructions: influences patient uptake and physician comfort.
• Suitability for OTC transitions (if applicable) or Rx-to-OTC marketing shifts: impacts channel distribution and pricing.

A precise timeline requires the NDA/label history and whether Rhinocort Allergy is being marketed as an Rx product, OTC product, or under specific switching arrangements.

What manufacturing and supply chain dynamics can affect Rhinocort Allergy sales?

INCS supply volatility is less about active ingredient scale than:

• contract manufacturing capacity for finished dosage forms,
• consistency of suspension attributes,
• device line throughput (spray/metering systems),
• packaging constraints during seasonal demand.

These factors can produce short-lived quarter skews even when underlying demand is stable.

How do seasonal patterns impact quarterly revenue for Rhinocort Allergy?

Seasonal demand is a major driver for INCS. Model-ready conclusions:

• Q2 and Q3 typically capture larger allergic rhinitis demand; Q1/Q4 soften depending on climate and perennial symptom prevalence.
• Promotional intensity often increases before peak season to secure retailer and pharmacy inventory positions.

For financial forecasting, seasonality matters more than long-term trend changes.

Commercial strategy: what drives price, access, and share for Rhinocort Allergy?

Pricing and gross-to-net

• Net performance is sensitive to rebate structures tied to formulary tiering and volume.
• Share shifts to preferred products often reduce effective net pricing even when wholesale prices remain stable.

Access and contracting

• “Preferred” INCS placement is the main lever for persistence.
• Step therapy and prior authorization can delay switching and reduce capture of newly diagnosed patients.

Device and user experience

• Even with identical active ingredients, patient preference affects refill rates.
• Better device adoption can sustain share against cost-driven generic substitution.

How does Rhinocort Allergy compare with key competing INCS products in market position?

The most actionable comparison is not efficacy head-to-head, but formulary placement and device acceptance. In mature INCS classes:

• brands win where they have payer preference, favorable copays, or superior device perception,
• generics win where they are “default” covered products with minimal friction.

A complete competitor-by-competitor chart requires drug-by-drug net sales and US payer placement data tied to the same time window.

What generic entry risks exist for Rhinocort Allergy?

Generic entry risk is best evaluated by:

• remaining exclusivities tied to the specific NDA/configuration,
• active patent claims on formulation or device specifics,
• ANDA readiness and expected launch dates.

Without the exact Orange Book identifiers for Rhinocort Allergy, the generic launch risk cannot be translated into a litigation-calendar view.

Key takeaways on Rhinocort Allergy’s financial trajectory

• Rhinocort Allergy’s revenue path is governed by mature-category dynamics: seasonal demand, payer economics, and class-level substitution.
• Generic and competitive pressure typically compresses growth and shifts performance toward share stability rather than expansion.
• Future upside or downside depends on the remaining product-specific IP and exclusivity status for the exact marketed configuration, plus device/user-experience factors that influence persistence.
• Forecasting requires seasonality-aware modeling and gross-to-net assumptions tied to formulary contracting cycles.

FAQs

1) When do intranasal budesonide products typically lose exclusivity and face accelerated substitution?

Exclusivity loss generally aligns with the end of listed patent terms and any product-specific exclusivity windows tied to the NDA and formulation configuration, after which PBMs accelerate preferred generic substitution.

2) How do PBM formularies influence Rhinocort Allergy net sales more than wholesale pricing?

PBM tiers and contracting volume targets drive rebates and copay positioning, often determining realized net sales even when list prices change slowly.

3) What rollout risks affect intranasal brands during peak allergy season?

Finished-goods manufacturing capacity, device/spray component throughput, and packaging lead times can create short-lived supply constraints that distort quarterly sales.

4) Can device or formulation differences sustain a brand versus generics in INCS?

Yes, where patient experience differences reduce non-medical switching and improve persistence, brands can hold share even amid lower-priced generics.

5) What should investors watch to predict Rhinocort Allergy revenue changes next year?

Track seasonal inventory cycles, formulary tier movement, and any changes in Orange Book-listed protections tied to the exact Rhinocort Allergy marketed NDA/configuration.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
2. FDA. Drug Approval Reports and labeling history for budesonide nasal corticosteroid products. (Accessed 2026).